Clinical Trials Logo

Apheresis Related Complication clinical trials

View clinical trials related to Apheresis Related Complication.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05894317 Recruiting - Clinical trials for Vascular Access Complication

Vascular Access Complications for Therapeutic Apheresis in Nephrology

VACTANE
Start date: June 1, 2020
Phase:
Study type: Observational

The aim of this study is to describe vascular access complications which are used for therapeutic apheresis in Nephrology.

NCT ID: NCT05181969 Recruiting - Clinical trials for Cardiovascular Diseases

Long-term Characterization of Lipoprotein Apheresis Technologies for Individual Device Adaption (LOLIDA)

LOLIDA
Start date: October 1, 2014
Phase:
Study type: Observational [Patient Registry]

Lipoprotein apheresis is often applied as the final treatment of patient with severe and medication resistant dyslipidemia and progressive atherosclerosis. The high effectiveness of lipoprotein apheresis to improve the patient's metabolic situation and thereby strongly minimize the incidence of cardiovascular events was confirmed by a variety of studies. While in the past years, mostly patients with severe homo- or heterozygous familial hypercholesterolemia (FH) or otherwise highly elevated LDL-cholesterol were subjected to lipoprotein apheresis, currently the major indication for lipoprotein apheresis is a critical elevated plasma level of lipoprotein (a) [Lp(a)] in patients with severe cardiovascular events. Even if it is now widely accepted that Lp(a) is an independent risk factor for cardiovascular diseases due to its pro-atherogenic potential, the exact molecular mechanisms by which Lp(a) contributes to the atherosclerotic process remain unclear. Despite rigorous reduction of plasma Lp(a)-levels during lipoprotein apheresis newly occurring cardiovascular events cannot prevented in all patients. Specific pleiotropic effects of apheresis technologies are supposed to be critically involved in the clinical outcome. By measurement of a wide variety of cardio-metabolic biomarkers playing a role in inflammation, endothelial dysfunction, lipid metabolism or blood pressure regulation during repeated Lp(a) lowering by various apheresis methods may allow the identification of clusters of risk factors determining clinical outcome and give the biological basement for an optimized individual lipoprotein apheresis therapy.